ention of relapse of duodenal ulcer in H. pylori negative patients or when H. pylori eradication is not possible the recommended dose is Ulcid 20 mg once daily. In some patients a daily dose of 10 mg may be sufficient. In case of therapy failure, the dose can be increased to 40 mg.
Treatment of gastric ulcers
The recommended dose is Ulcid 20 mg once daily. In most patients healing occurs within four weeks. For those patients who many not be fully healed after initial course, healing usually occurs during a further four weeks treatment period. In patients with poorly responsive gastric ulcer Ulcid 40 mg once daily is recommended and healing is usually achieved within eight weeks.
Prevention of relapse of gastric ulcers
For the prevention of relapse in patients with poorly responsive gastric ulcer the recommended dose is Ulcid 20 mg once daily. If needed the dose can be increased to Ulcid 40 mg once daily.
H. pylori eradication in peptic ulcer disease
For the eradication of H. pylori the selection of antibiotics should consider the individual patient's drug tolerance, and should be undertaken in accordance with national, regional and local resistance patterns and treatment guidelines.
• Ulcid 20mg + clarithromycin 500mg + amoxicillin 1,000mg, each twice daily for one week, or
• Ulcid 20 mg + clarithromycin 250 mg (alternatively 500mg) + metronidazole 400 mg (or 500 mg or tinidazole 500mg), each twice daily for one week, or
• Ulcid 40 mg once daily with amoxicillin 500 mg and metronidazole 400 mg (or 500 mg or tinidazole 500 mg), both three times a day for one week.
In each regimen, if the patient is still H. pylori positive, therapy may be repeated.
Treatment of NSAID-associated gastric and duodenal ulcers
For the treatment of NSAID-associated gastric and duodenal ulcers, the recommended dose is Ulcid 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period.
Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk
For the prevention of NSAID associated gastric ulcers or duodenal ulcers in patients at risk (age> 60, previous history of gastric and duodenal ulcers, previous history of upper GI bleeding) the recommended dose is Ulcid 20 mg once daily.
Treatment of reflux esophagitis
The recommended dose is Ulcid 20 mg once daily. In most patients healing occurs within four weeks. For those patients who many not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period.
In patients with severe esophagitis Ulcid 40 mg once daily is recommended and healing is usually achieved within eight weeks.
Long-term management of patients with healed reflux esophagitis
For the long-term management of patients with healed reflux esophagitis the recommended dose is omeprazole 10 mg once daily. If needed, the dose can be increased to Ulcid 20-40 mg once daily.
Treatment of symptomatic gastro-esophageal reflux disease
The recommended dose is Ulcid 20 mg daily. Patients may respond adequately to 10 mg daily, and therefore individual dose adjustment should be considered.
If symptom control has not been achieved after 4 weeks treatment with Ulcid 20 mg daily, further investigation is recommended.
Treatment of Zollinger-Ellison syndrome:
In patients w